New research from the New England Journal of Medicine, outlines more evidence to support the effectiveness of cannabis to reduce seizures in epileptic children with Dravet syndrome.
Epilepsy is a neurological disease that causes various forms of seizures, ranging from undetectable to full-body convulsions. There are six main types of seizures associated with Epilepsy: clonic, tonic, tonic-clonic, myoclonic, absence and atonic seizures. According to the latest estimates, around 5.1 million children and adults in the US have had an epilepsy diagnosis or seizure disorder. The Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate.
This particular study was a double-blind, placebo-controlled trial, where 120 children and young adults with Dravet syndrome were randomly assigned cannabidiol or placebo. What they were measuring, was the change in convulsion-seizure frequency over a 14-week treatment period.
The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo. The patient’s overall condition improved by at least one category on the seven-category Caregiver Global Impression of Change scale in 62% of the cannabidiol group as compared with 34% of the placebo group. [New England Journal of Medicine]
To hear a real story of someone we are working with, watch this mother talk about how 420 Clinic and medical cannabis are helping her epileptic son live a normal life for the first time.